---
layout: default
title: Ampicillin Sodium
parent: 僅模型預測 (L5)
nav_order: 71
evidence_level: L5
indication_count: 0
---

# Ampicillin Sodium
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Ampicillin Sodium: Drug Repurposing Evaluation — Insufficient Data for Prediction

## One-Sentence Summary

Ampicillin Sodium is a well-known broad-spectrum beta-lactam antibiotic, originally used to treat a wide range of bacterial infections. However, the current Evidence Pack contains **no TxGNN-generated repurposing predictions**, and critical data fields — including mechanism of action, approved indications, and safety information — are marked as gaps. Without predicted indications or supporting evidence, a complete repurposing evaluation **cannot be conducted at this time**.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available in current data |
| Predicted New Indication | **None** — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A (No predictions generated) |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 8 |
| Recommended Decision | **Hold** |

---

## Why Is This Prediction Reasonable?

No TxGNN repurposing prediction was generated for Ampicillin Sodium in this Evidence Pack. Therefore, a mechanism-based rationale for a new indication **cannot be presented**.

From general pharmacological knowledge, Ampicillin Sodium is an aminopenicillin antibiotic that inhibits bacterial cell wall synthesis by irreversibly binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking. It has broad-spectrum activity against both Gram-positive and Gram-negative organisms. Its established clinical use covers infections of the respiratory tract, urinary tract, gastrointestinal tract, and meningitis.

Detailed mechanism of action data (MOA) is not available in the current Evidence Pack. Should TxGNN predictions become available in a future data run, this section will be updated to explain the biological plausibility of any new indication.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for a predicted new indication, as no repurposing prediction was generated.

---

## Literature Evidence

Currently no related literature available for evaluation, as no repurposing prediction was generated.

---

## Malaysia Market Information

The query log confirms **8 active registrations** with Malaysia's National Pharmaceutical Regulatory Agency (NPRA). However, the detailed license records returned in this data package contain no populated fields (product name, dosage form, and approved indication are all blank). The table below reflects the current data state:

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------------------|-------------|-------------|-------------------|
| — | — | — | — |
| — | — | — | — |
| — | — | — | — |
| — | — | — | — |
| — | — | — | — |

> **Note:** 8 licenses are confirmed as registered by NPRA query (2026-03-27), but granular license details were not returned in this dataset. Retrieval from the NPRA portal directly is recommended to populate this table.

---

## Safety Considerations

Please refer to the package insert for safety information.

> All safety fields (key warnings, contraindications, and drug interactions) are currently unavailable in this data package. No drug-drug interaction records were found in the DDI query. Full safety review must be deferred until package insert data is obtained from the NPRA official source.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN prediction pipeline returned no repurposing candidates for Ampicillin Sodium in this run, and all drug-level data fields critical to evaluation — including approved indications, mechanism of action, and safety warnings — are currently data gaps. There is no actionable evidence basis to proceed with a repurposing assessment.

**To proceed, the following is needed:**

- **[DG001 — Blocking]** Obtain the NPRA-approved package insert (PDF) and extract warnings, contraindications, and approved indications; this is required before any safety screening can begin
- **[DG002 — High]** Retrieve DrugBank entry for Ampicillin Sodium (DrugBank ID currently null) to populate MOA, categories, and toxicity data
- **Re-run TxGNN pipeline** after confirming correct INN-to-DrugBank mapping; the absence of a DrugBank ID (`drugbank_id: null`) is the most likely cause of the empty predictions list
- **Populate NPRA license details** — retrieve full registration records including product name, dosage form, manufacturer, and approved indication text for all 8 licenses
- Once predictions are available, re-evaluate evidence level and update the recommended decision accordingly
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

